Castellano | Euskara | Français | English
DAR No 4. Febuxostat (Adenuric) in chronic hyperuricaemia with urate deposits
Share it
What is painful for the patient are gout flares
- Febuxostat has shown a greater reduction in the levels of uric acid than fixed-dose (300 mg/d) allopurinol. With no titration of this dose, it is possible that the compared efficacy of febuxostat is overestimated.
- This drug has not proven more effective than allopurinol in reducing the frequency of gout attacks.
- The long-term safety profile is unknown, in particular with regard to cardiac-related events and other affectations of the liver, blood and thyroid gland. Cases of severe hypersensitivity including Stevens Johnson syndrome, acute anaphylaxis and shock, and liver failure have been notified.
- The cost of treatment with febuxostat is much higher than allopurinol.
